Circulation:药费对ASCVD患者治疗不依从性的影响

2019-12-22 QQY MedSci原创

药物治疗不依从性与动脉粥样硬化性心血管疾病(ASCVD)患者的不良预后相关,这类患者需要长期治疗以进行二级预防。目前尚不清楚药物成本对药物治疗不依从性的有多大的影响。在一项针对美国成年人的全国性代表性调查中进行了全国健康调查中(2013-2017),研究人员筛选其中年满18岁的有ASCVD病史的个体。如果在过去的12个月里,受试者报告说他们为了省钱而跳过剂量、少吃药物,或延迟服药,那么他们就被认为

药物治疗不依从性与动脉粥样硬化性心血管疾病(ASCVD)患者的不良预后相关,这类患者需要长期治疗以进行二级预防。目前尚不清楚药物成本对药物治疗不依从性的有多大的影响。

在一项针对美国成年人的全国性代表性调查中进行了全国健康调查中(2013-2017),研究人员筛选其中年满18岁的有ASCVD病史的个体。如果在过去的12个月里,受试者报告说他们为了省钱而跳过剂量、少吃药物,或延迟服药,那么他们就被认为成本相关的不依从性(CRN)。

共14 279位ASCVD个体,220万人(12.6%)有CRN,其中150万人为跳过剂量、160万人为少吃药物、190万人为延迟服药。年龄小于65岁、女性、低家庭收入、缺乏健康咨询和高疾病负荷均与CRN独立相关,在这些亚组中,CRN的发生率高达20%。与无CRN患者相比,CRN患者要求低成本药物治疗的概率高10.8倍,使用非处方药替代治疗的概率高8.9倍。

每8例ASCVD患者中就有1例报告由于费用问题而没有坚持服药。消除获取药物的经济障碍,特别是在弱势患者群体中,可能有助于提高对基本治疗的坚持,从而降低ASCVD发病率和死亡率。

原始出处:

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2043113, encodeId=6a9b2043113e3, content=<a href='/topic/show?id=e619645e37f' target=_blank style='color:#2F92EE;'>#治疗不依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64573, encryptionId=e619645e37f, topicName=治疗不依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Thu Mar 19 22:18:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939011, encodeId=df311939011eb, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Feb 25 06:18:00 CST 2020, time=2020-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271123, encodeId=442c12e112352, content=<a href='/topic/show?id=6929284181' target=_blank style='color:#2F92EE;'>#ASCVD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2841, encryptionId=6929284181, topicName=ASCVD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Tue Dec 24 08:18:00 CST 2019, time=2019-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319344, encodeId=251613193440b, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Tue Dec 24 08:18:00 CST 2019, time=2019-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446245, encodeId=1c711446245ee, content=<a href='/topic/show?id=f8cb8e958ae' target=_blank style='color:#2F92EE;'>#药费#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87958, encryptionId=f8cb8e958ae, topicName=药费)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=0Yy1x0ia6yKWyKUaG6Ja0UA&s=100&t=1564295847, createdBy=646f5195679, createdName=bshuang, createdTime=Tue Dec 24 08:18:00 CST 2019, time=2019-12-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2043113, encodeId=6a9b2043113e3, content=<a href='/topic/show?id=e619645e37f' target=_blank style='color:#2F92EE;'>#治疗不依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64573, encryptionId=e619645e37f, topicName=治疗不依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Thu Mar 19 22:18:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939011, encodeId=df311939011eb, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Feb 25 06:18:00 CST 2020, time=2020-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271123, encodeId=442c12e112352, content=<a href='/topic/show?id=6929284181' target=_blank style='color:#2F92EE;'>#ASCVD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2841, encryptionId=6929284181, topicName=ASCVD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Tue Dec 24 08:18:00 CST 2019, time=2019-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319344, encodeId=251613193440b, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Tue Dec 24 08:18:00 CST 2019, time=2019-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446245, encodeId=1c711446245ee, content=<a href='/topic/show?id=f8cb8e958ae' target=_blank style='color:#2F92EE;'>#药费#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87958, encryptionId=f8cb8e958ae, topicName=药费)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=0Yy1x0ia6yKWyKUaG6Ja0UA&s=100&t=1564295847, createdBy=646f5195679, createdName=bshuang, createdTime=Tue Dec 24 08:18:00 CST 2019, time=2019-12-24, status=1, ipAttribution=)]
    2020-02-25 quxin068
  3. [GetPortalCommentsPageByObjectIdResponse(id=2043113, encodeId=6a9b2043113e3, content=<a href='/topic/show?id=e619645e37f' target=_blank style='color:#2F92EE;'>#治疗不依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64573, encryptionId=e619645e37f, topicName=治疗不依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Thu Mar 19 22:18:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939011, encodeId=df311939011eb, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Feb 25 06:18:00 CST 2020, time=2020-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271123, encodeId=442c12e112352, content=<a href='/topic/show?id=6929284181' target=_blank style='color:#2F92EE;'>#ASCVD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2841, encryptionId=6929284181, topicName=ASCVD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Tue Dec 24 08:18:00 CST 2019, time=2019-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319344, encodeId=251613193440b, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Tue Dec 24 08:18:00 CST 2019, time=2019-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446245, encodeId=1c711446245ee, content=<a href='/topic/show?id=f8cb8e958ae' target=_blank style='color:#2F92EE;'>#药费#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87958, encryptionId=f8cb8e958ae, topicName=药费)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=0Yy1x0ia6yKWyKUaG6Ja0UA&s=100&t=1564295847, createdBy=646f5195679, createdName=bshuang, createdTime=Tue Dec 24 08:18:00 CST 2019, time=2019-12-24, status=1, ipAttribution=)]
    2019-12-24 doctorzheng
  4. [GetPortalCommentsPageByObjectIdResponse(id=2043113, encodeId=6a9b2043113e3, content=<a href='/topic/show?id=e619645e37f' target=_blank style='color:#2F92EE;'>#治疗不依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64573, encryptionId=e619645e37f, topicName=治疗不依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Thu Mar 19 22:18:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939011, encodeId=df311939011eb, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Feb 25 06:18:00 CST 2020, time=2020-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271123, encodeId=442c12e112352, content=<a href='/topic/show?id=6929284181' target=_blank style='color:#2F92EE;'>#ASCVD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2841, encryptionId=6929284181, topicName=ASCVD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Tue Dec 24 08:18:00 CST 2019, time=2019-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319344, encodeId=251613193440b, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Tue Dec 24 08:18:00 CST 2019, time=2019-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446245, encodeId=1c711446245ee, content=<a href='/topic/show?id=f8cb8e958ae' target=_blank style='color:#2F92EE;'>#药费#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87958, encryptionId=f8cb8e958ae, topicName=药费)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=0Yy1x0ia6yKWyKUaG6Ja0UA&s=100&t=1564295847, createdBy=646f5195679, createdName=bshuang, createdTime=Tue Dec 24 08:18:00 CST 2019, time=2019-12-24, status=1, ipAttribution=)]
    2019-12-24 fyxzlh
  5. [GetPortalCommentsPageByObjectIdResponse(id=2043113, encodeId=6a9b2043113e3, content=<a href='/topic/show?id=e619645e37f' target=_blank style='color:#2F92EE;'>#治疗不依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64573, encryptionId=e619645e37f, topicName=治疗不依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Thu Mar 19 22:18:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939011, encodeId=df311939011eb, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Feb 25 06:18:00 CST 2020, time=2020-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271123, encodeId=442c12e112352, content=<a href='/topic/show?id=6929284181' target=_blank style='color:#2F92EE;'>#ASCVD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2841, encryptionId=6929284181, topicName=ASCVD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Tue Dec 24 08:18:00 CST 2019, time=2019-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319344, encodeId=251613193440b, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Tue Dec 24 08:18:00 CST 2019, time=2019-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446245, encodeId=1c711446245ee, content=<a href='/topic/show?id=f8cb8e958ae' target=_blank style='color:#2F92EE;'>#药费#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87958, encryptionId=f8cb8e958ae, topicName=药费)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=0Yy1x0ia6yKWyKUaG6Ja0UA&s=100&t=1564295847, createdBy=646f5195679, createdName=bshuang, createdTime=Tue Dec 24 08:18:00 CST 2019, time=2019-12-24, status=1, ipAttribution=)]
    2019-12-24 bshuang